Introduction
Neisseria gonorrhoeae, the causative agent of the sexually transmitted infection gonorrhea, is a Gram-negative diplococcus and is strictly a human pathogen. Clinical isolates of N.gonorrhoeae frequently exhibit high levels of antimicrobial resistance by multiple mechanisms that include porin (uptake), cellular targets of the antibiotics, and active efflux of anti-microbials by efflux pumps. [1] [2] [3] [4] The efflux-mediated resistance to fluoroquinolones which is well-recognised in a number of Gram-negative bacteria has also been reported in N.gonorrhoeae. [5, 6] Susceptibility to ciprofloxacin, ofloxacin, and norfloxacin (AB BioDisk, Solna, Sweden) lomefloxacin (Hi media laboratories, Mumbai, India) was determined by E test according to the manufacturer's instructions. The MIC of all the isolates for enoxacin (Sigma chemical) was determined by agar dilution method using GC agar base and vitamin growth supplement (Hi media laboratories, Mumbai, India). World Health Organisation (WHO) reference strains A, G, L received under WHO Gonococcal Antimicrobial Surveillance Programme from WHO GASP South East Asia Region Reference Laboratory, New Delhi, ATCC 49226 and 8 sensitive strains were included as quality controls. The strains were defined as susceptible (S), intermediate susceptible (I) and resistant (R) according to the breakpoints proposed by the Clinical and Laboratory Standards Institute (CLSI). [12] Polymerase chain reaction (PCR) and direct deoxyribonucleic acid (DNA) sequencing were performed to identify mutations in mtrR genes of the gonococcal isolates. The mtrR genes were amplified using PCR primers as reported by Dewi et al. 2004 . [5] The PCR amplification was performed in 25 ul of a reaction mixture which contained 2.5 ul of 10× Taq polymerase buffer (500 mM KCl, 100 mM Tris-HCl [pH 8.3], 15 mM MgCl2, 0.1% gelatin), 1 ul of each of the primers (25 pmol/¼ r ), 2.5 ul r of each of the deoxynucleoside triphosphates (10 mM), 0.2 ul of Taq DNA polymerase (5 U/¼ r ) (Bangalore genei, India), and 10 ul r of template DNA. Thirty-five cycles were performed for each reaction. Each cycle consisted of 30 s at 94°C, 1 min at 60°C, and 1 min at 72°C and final extension at 72°C at 5 mins.
Amplicons were separated by 1.5% agarose gel stained with ethidium bromide for visualisation. DNA was purified using Qiagen DNA purification kit (Minielute ® PCR purification kit, Qiagen GmbH, Hilden, Germany). The purified DNA was sequenced using a Big Dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster, USA) and an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) following the manufacturer's instructions. Mutations were identified by comparing translated amino acid sequences to reference sequence GenBank accession no. Z 25796. World Health Organisation (WHO) reference strains A, G, L received under WHO Gonococcal Antimicrobial Surveillance Programme from WHO GASP South East Asia Region Reference Laboratory, New Delhi were included as quality controls.
The data was analysed using Statistical Package for the Social Sciences (SPSS) 15.0 for windows (SPSS Inc. 1989 -2006 . Association of mutation patterns with quinolone resistance were analysed using the Pearson's Chi-square test and Fisher's exact tests using SPSS 10.0 (SPSS Inc. Chicago, II, United states). A P value of < 0.05 was considered to be significant.
Results
Antibiotic susceptibility testing of all the strains revealed that 98.4% of the strains were resistant to norfloxacin and ofloxacin, 96.9% to enoxacin and ciprofloxacin, 95.3% to lomefloxacin. The strains resistant to all the antibiotics showed high MIC value (≥8 ug/ml).
Thirty-one (48.4%) of the N.gonorrhoeae strains showed mutations in the mtrR gene. Of these, nine (14%) of N.gonorrhoeae strains showed ≥ 3 mutations in mtrR gene, twenty-one (32.8%) strains showed double mutations, and one (3.1%) strain showed single mutation. Asp-79 → Asn, Arg-98 → Gln, Tyr-105 → His, Asn-110 → Ser (9.4%) was the common mutation found in the strains (n = 9) showing ≥ 3 mutations in mtrR gene followed by Ala-39 → Thr, Leu-47 → Pro, Tyr-105 → His (3.1%), Ala-77 → Thr, Ala-78 → Glu, Thr-86 → Ala in (1.6%). All these strains showed resistant to all the five antibiotics (MIC ≥ 8 ug/ml). Gly-45 → Asp, Tyr-105 → His (25%) was common mutation, followed by Ala-39 → Thr, Tyr-105 → His (3.1%), Ala-78 → Glu, Thr-86 → Ala (1.6%), Asp-79 → Asn, and Tyr-105 → His (1.6%) in strains showing double mutations and single mutation.
Thirty-three strains did not show any mutations in mtrR gene. Of these thirty-three strains, five were resistant to ≤ 4 antibiotics with MICs value of ≤ 0.032 ug/ml [ Table 1 and Figure 1 ]. The MICs level of these isolates were significantly associated (P < 0.001) with the number of mutations in the mtrR gene.
WHO A strain, which is sensitive to all antibiotics (MIC of ≤ 0.016 ug/ml) had no mutations in the mtrR gene while WHO L and WHO G (MIC >=4 ug/ml) had single mutation at codon 45 (Gly-45 → Asp).
Discussion
The emergence and dissemination of resistance to antimicrobial agents among N. gonorrhoeae isolates have limited the variety of drugs that can be used for the treatment of gonococcal infections. Quinolones became popular therapy during the 1980s and were widely used as effective oral therapy against penicillin-resistant N gonorrhoeae. Ciprofloxacin, one of the quinolone has been one of the recommended first-line therapies for these infections worldwide, including in India. However, a number of studies have revealed an increasing frequency of ciprofloxacin-resistant N. gonorrhoeae isolates in different geographic regions. [13, 14] Due to increase in quinolone resistance, cephalosporins were the only recommended class of drugs for treatment of gonococcal infections worldwide. The current regimens for treatment of gonorrhea in all [15] The mutations in the promoter and the encoding region of the mtrR gene may contribute to high level of quinolone resistance in N. gonorrhoeae due to increased expression of the proteins of the MtrCDE system. [3] Here, we studied the mutations in the mtrR gene in quinolone resistance strains of N.gonorrhoeae and the results are being presented.
Since the discovery of the mtrR repressor and the realisation that it controls mtrRCDE expression in N. gonorrhoeae, the studies carried out in the 1990s examined the impact of mtrR mutations on gene expression and antibiotic resistance endowed by the MtrC-MrD-MtrE efflux pump. [3] Recognising its importance, recent investigations included this locus along with others to study the resistance determinants. It was found that certain mtr mutations, A39T or G45D in the mtrR DNA-binding domain or H105Y and the E202G that impact the C-terminal region of mtrR are repeatedly detected in the quinolone resistant isolates. [7, 8] Sequence analysis of the mtrR coding region of our isolate showed the presence of Gly-45 → Asp, Ala-39 → Thr, Tyr-105 → His mutations which were also described by others. [5, 10, 16] In addition, we observed Leu-47 → Pro, Thr-86 → Ala, Arg-98 → Gln mutation which has not been reported so far. All the strains (n = 31) showed multiple mutations except one strains which showed single mutation at codon 45. The strains resistant to all antibiotics were significantly associated with presence of multiple mutations in the mtrR genes (P < 0.01). All these To our knowledge, this is the first study from India that has detected mtrR mutations in N.gonorrhoeae strains resistant to various quinolones. In conclusion, single or multiple mutations in mtrR gene may have resulted in increased resistance to quinolone and thus may limit the drug choice for gonorrhea. It is important to stress continued research on antibiotic resistance to further understand the mechanism responsible for antibiotic resistance in N.gonorrhoeae.
